India  

Oxford–AstraZeneca COVID-19 vaccine

Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

Oxford–AstraZeneca COVID-19 vaccine    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Oxford–AstraZeneca COVID-19 vaccine: Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca
The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.

0
shares
ShareTweetSavePostSend
 

You Might Like


Corbevax maker seeks emergency use approval as booster jab for adults vaccinated with Covishield, Covaxin

There were 416 patients aged 18 to 80 who got two doses of Covaxin or Covishield, the last one six months before the Corbevax booster.
DNA - Published

Breakthrough Delta infection, reinfection with Omicron in person vaccinated with Covishield

The patient received the first dose of Covishield vaccine on January 31, 2021, and the second dose on March 3, 2021.
DNA - Published

Covid Update: Get Covaxin, Covishield at Rs 225

Price slash of Covaxin and Covishield was announced after the government allowed all above 18 years of age can get booster dose from April 10.
DNA - Published

Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shot


IndiaTimes - Published

Covishield, Covaxin prices slashed ahead of booster drive expansion

Serum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..
IndiaTimes - Published

Serum Institute of India prices Covishield booster dose at Rs 600

SII CEO Adar Poonawalla also welcomed the government's move to allow precautionary doses of the vaccine to all aged above 18 years.
DNA - Published

Serum Institute's Covishield precaution dose priced at Rs 600 per shot

Vaccine maker Serum Institute of India (SII) on Friday said the precaution dose of its Covishield vaccine against Covid-19 will be priced at Rs 600 per shot for eligible individuals.
IndiaTimes - Published

ICMR study shows increase in antibodies after receiving Covaxin booster dose, says MoS Health

International data available on booster doses of AstraZeneca & Covishield suggests 3 to 4 fold increase in antibody levels after their administration.
DNA - Published

As cases rise elsewhere, govt set to cut Covishield shots gap

The government’s top vaccination advisory panel, National Technical Advisory Group on Immunisation (NTAGI), has recommended reducing the interval between the two primary doses of Covishield to 8-16..
IndiaTimes - Published

Gap between first and second Covishield vaccine doses reduced to 8-16 weeks

Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
DNA - Published

Second Covishield dose can be given between 8-16 weeks after first dose, says NTAGI reducing gap


IndiaTimes - Published

Mixing Covishield & Covaxin gives better immunity: ICMR


IndiaTimes - Published

SII urges Mandaviya to reduce gap between 2nd, precaution dose of Covishield from 9 to 3 months


IndiaTimes - Published

Media reports claiming 50 lakh unused Covishield doses may go waste by month end 'misleading': Govt

The Union health ministry on Thursday refuted as “misleading” media reports which claimed that 50 lakh unused Covishield doses may go waste by the end of this month. It said the Centre had..
IndiaTimes - Published

Serum Institute has applied for full market authorisation of Covishield: CEO Adar Poonawala

Serum Institute has applied to the Indian health ministry and Central Drugs Standard Control Organisation (CDSCO) for full market authorisation for its Covishield vaccine, company's CEO Adar Poonawalla..
IndiaTimes - Published

India-Bangladesh bonhomie scaled new heights as 2021 marked 50 years of ties

The year began on a promising note as Bangladesh PM Sheikh Hasina thanked her Indian counterpart Narendra Modi for sending over two million doses of AstraZeneca-Oxford University vaccine Covishield, as..
IndiaTimes - Published

Covishield cover high 7 months after 2 doses, 90% antibody prevalence seen: Study


IndiaTimes - Published

Covishield production capacity 250-275 million doses a month, Covaxin 50-60 million: Govt


IndiaTimes - Published

ICMR focus on two-dose vax, is fine with current Covishield gap


IndiaTimes - Published

Government panel rejects SII's plea to administer a third dose of Covishield vaccine

SII sought approval to administer the third dose on the basis of adequate stock of Covishield and rising demand for boosters amid emergence of Omicron
DNA - Published

CDSCO panel seeks local clinical trial data from SII for approval of Covishield as booster dose


IndiaTimes - Published

Subject Expert Committee to meet on Dec 10 to discuss approval for Covishield booster dose


IndiaTimes - Published

Not enough orders, may cut Covishield output by 50%: SII

With not enough orders for Covishield from the Centre, Serum Institute of India CEO Adar Poonawalla on Tuesday said the company is looking at slashing monthly production of vaccines by at least 50% %...
IndiaTimes - Published

Covid-19: A wide range of vaccines act as booster to AstraZeneca, Pfizer shots, says study

Up to six different Covid-19 boosters were found to be safe, and provoked strong immune responses in people who have previously received a two-dose course of the Oxford-AstraZeneca-developed..
IndiaTimes - Published

As Omicron fear intensifies, Serum Institute of India seeks DCGI's approval for Covishield booster shot

Recently, Kerala, Rajasthan, Karnataka, and Chhattisgarh have also urged the Centre to decide on allowing booster doses of the COVID-19 vaccine.
DNA - Published Also reported by •IndiaTimes

How effective is Covishield against Omicron? SII CEO Adar Poonawalla says this

In India, no cases of the new variant have been detected yet, but the government says it is preparing to deal with it.
DNA - Published

Can Covishield, Covaxin provide protection against Omicron variant? Here's what experts are saying

As the Omicron variant spreads to multiple countries, people are wondering if Indian vaccines will be effective against the new COVID-19 variant.
DNA - Published

Expert: Covishield, Covaxin may offer protection against Omicron


IndiaTimes - Published

India vows to stand by Africa, says all Covax orders cleared

Expressing support for Africa, which has been rattled by the discovery of Covid-19 variant Omicron, the government on Monday announced it had cleared all orders placed so far by the UN-backed Covax..
IndiaTimes - Published

India willing to supply Covishield, Covaxin: Mandaviya to Latin American, Caribbean envoys

Interacting with ambassadors of Latin American and Caribbean nations, Union Health Minister Mansukh Mandaviya on Thursday said India is willing to supply Covishield and Covaxin to these countries...
IndiaTimes - Published

New Zealand adds Covishield, Covaxin to approved COVID-19 vaccine list

Now, travellers who got jabbed with the Covishield or Covaxin shot can enter New Zealand without a quarantine period.
DNA - Published

Extended Covishield dosage gap more potent, show studies

The extended gap of at least 12 weeks between the two doses of Covishield has resulted in better immune response among majority of vaccinated Indians, subsiding any immediate requirement for booster..
IndiaTimes - Published

Saudi Arabia recognises Serum Institute's Covishield, exempts quarantine for fully vaccinated

Covishield vaccine approval enables fully vaccinated Indian travellers to enter Saudi Arabia without having to undergo institutional quarantine.
DNA - Published

Canada yet to recognise Covaxin even after WHO nod

In a re-run of the UK’s delay in accepting WHO-approved and made-in-India Covishield, Canada is yet to recognise Covaxin even after World Health Organisation (WHO) gave emergency use listing for..
IndiaTimes - Published

Covid-19 vaccination: 'No shortage for door-to-door drive'

Ahead of the proposed door to door vaccination drive by the centre, national task force members have ruled out any shortage of vaccines for the drive with nearly 30 crore vaccines to be procured from..
IndiaTimes - Published

Australia recognises Covaxin, to allow visitors jabbed with it; Modi thanks Oz counterpart

Australia will recognise Covaxin, apart from Covishield, allowing those fully jabbed with the Bharat Biotech vaccine entry into the country. While WHO’s emergency use listing for Covaxin is awaited,..
IndiaTimes - Published

SC says 'it will wait for WHO's response over Covaxin recognition'

The Supreme Court on Friday said that "it will wait for the response of the World Health Organisation (WHO) over Covaxin recognition." and cannot simply direct the Centre to revaccinate people with..
IndiaTimes - Published

Cannot play with lives of people by directing revaccination with Covishield without any data: SC

"We cannot play with the lives of people by directing Centre to revaccinate. We don't have any data with us. We have read in newspapers that Bharat Biotech has filed an application with the World..
IndiaTimes - Published

Supreme Court refuses to entertain plea against mass Covid vaccination of Covishield and Covaxin

The Supreme Court of India on Monday refused to entertain a plea against the mass vaccination of Covishield and Covaxin. The top court observed that vaccination is the key to protect people from Covid...
IndiaTimes - Published

Will have enough doses for booster shots, says Poonawalla

Adar Poonawalla, CEO of Serum Institute of India (SII), exuded confidence in meeting the Centre’s goal of immunising all adults by yearend, while announcing that Covid-19 vaccine for children,..
IndiaTimes - Published

India withdraws tit-for-tat Covid advisory for UK travellers

The government has reinstated its earlier guidelines by withdrawing a travel advisory issued on October 1 that made it mandatory for British nationals arriving in India to undergo a mandatory 10-day..
IndiaTimes - Published

India withdraws 10-day mandatory quarantine for UK passengers

The move comes to reciprocate the UK's decision to discontinue the mandatory quarantine and checks for Indian visitors vaccinated with Covishield.
DNA - Published

Next step is moving people between both nations, says envoy after UK accepts Covishield

UK high commissioner to India, Alex Ellis on Saturday said the next step post the India-UK cooperation on Covishield is to increase the flow of people between the two nations as they are desperate to..
IndiaTimes - Published

After tit for tat, UK recognises Serum Institute of India's Covishield, junks ‘discriminatory’ order

From October 11, Indians who have been fully vaccinated with WHO-approved Covishield will not be required to undergo the mandatory 10-day quarantine on arrival in the UK, ending a standoff between the..
IndiaTimes - Published

End of stalemate: Indians fully vaccinated with Covishield won't have to quarantine from October 11

People vaccinated with WHO-approved Covishield in India will from next Monday (Oct 11) not be required to undergo the mandatory 10-day quarantine on arrival in the UK. Britain has finally relented,..
IndiaTimes - Published

End of stalemate: Got Covishield jabs in India, no quarantine in UK from next Monday

People vaccinated with WHO-approved Covishield in India will from next Monday (Oct 11) not be required to undergo the mandatory 10-day quarantine on arrival in the UK. Britain has finally relented,..
IndiaTimes - Published

SII gets nod to send Covid vaccines to Nepal, Bangaldesh, Myanmar, bulk to AstraZeneca; Bharat Biotech to Iran

The government has permitted Serum Institute of India (SII) to export 10 lakh Covishield doses each to Nepal, Myanmar and Bangladesh, while Bharat Biotech will provide Iran with 10 lakh doses of..
IndiaTimes - Published

SII now aims to include kids aged 2 to 6 in vaccination trials in a month

The Serum Institute of India has expanded Covovax’s paediatric trial in seven to 11 years age bracket across 10 sites in India, including Pune, after ensuring vaccine safety in adolescents. The..
IndiaTimes - Published

UK's 'simplified' travel rules does not cover vaccinated Indians

Britain's so-called "simplified" international travel system that scraps an amber list of medium Covid-19 risk countries took effect on Monday, but it offers no benefits for vaccinated Indians..
IndiaTimes - Published

'I got Covishield from India': President of the 76th UN General Assembly Abdulla Shahid


IndiaTimes - Published


 Page 1  〉